Drysdale Simon B, Sande Charles J, Green Christopher A, Pollard Andrew J
a Oxford Vaccine Group, Department of Paediatrics , University of Oxford , Oxford , UK.
b NIHR Oxford Biomedical Research Centre, Level 2 , Children's Hospital , Oxford , UK.
Expert Rev Vaccines. 2016;15(2):149-52. doi: 10.1586/14760584.2016.1114419. Epub 2015 Dec 4.
Respiratory syncytial virus (RSV) infection is the most important cause of hospitalization in infants and is one of the leading global causes of infant mortality and as such its prevention through vaccination is a public health priority. While essential for the successful implementation of vaccine programs, there remains a paucity of data on the epidemiology of the virus in different settings and age groups and limited knowledge about virus transmission and the health-care costs of the disease. Such data are now needed to populate health economic models and to inform optimal approaches to disease control through vaccination.
呼吸道合胞病毒（RSV）感染是婴儿住院的最重要原因，也是全球婴儿死亡的主要原因之一，因此通过疫苗接种进行预防是公共卫生的优先事项。虽然对于疫苗计划的成功实施至关重要，但关于该病毒在不同环境和年龄组中的流行病学数据仍然匮乏，对病毒传播以及该疾病的医疗保健成本的了解也有限。现在需要这些数据来填充健康经济模型，并为通过疫苗接种控制疾病的最佳方法提供依据。
